Alpha-2 adrenergic receptor (ADRA2)

The alpha-2 adrenergic receptor is a G protein-coupled receptor (GPCR) that plays a pivotal role in the regulation of the sympathetic nervous system. It exists in three primary subtypes—alpha-2A, alpha-2B, and alpha-2C—and is predominantly coupled to Gi/o proteins, which inhibit adenylate cyclase and reduce intracellular cAMP levels. Biologically, these receptors function as presynaptic autoreceptors that provide negative feedback to inhibit the release of norepinephrine, thereby modulating arousal, pain transmission, and cardiovascular tone. In clinical practice, alpha-2 adrenergic receptors are key therapeutic targets for sedation, analgesia, and the management of hypertension and ADHD. Dexmedetomidine is a highly selective agonist for these receptors, particularly the alpha-2A subtype, and is widely used in intensive care and anesthesia for its unique conscious sedation profile, which allows patients to remain rousable despite deep sedation. However, its use requires careful monitoring due to potential cardiovascular side effects such as bradycardia and biphasic blood pressure responses.

Other names

Alpha-2 adrenoceptorAlpha-2 ARADRA2Alpha-2A adrenergic receptorAlpha-2B adrenergic receptorAlpha-2C adrenergic receptor

Dexmedetomidine acts as a highly selective agonist of alpha-2 adrenergic receptors, particularly in the locus coeruleus of the brainstem. Binding to these receptors inhibits the activity of adenylate cyclase and reduces cAMP levels, leading to the hyperpolarization of noradrenergic neurons and the suppression of norepinephrine release. This sympatholytic effect results in dose-dependent sedation, hypnosis, and anxiolysis. Additionally, activation of alpha-2 receptors in the dorsal horn of the spinal cord inhibits the release of nociceptive neurotransmitters like substance P, providing analgesic effects.